Dabigatran and Alogliptin: Interaction Details

Brand names
Dabigatran
Pradaxa
Alogliptin
Nesina
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

What Happens When You Take Dabigatran With Alogliptin

What can happen when they are taken together (rated Major)

Increased dabigatran exposure and an increased risk of bleeding

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Because giving dabigatran together with a may raise dabigatran exposure and the likelihood of bleeding, the combination should generally not be used,2 especially in patients with impairment. For adults taking dabigatran capsules to lower the risk of stroke and systemic embolism in non-valvular atrial fibrillation, should be avoided when CrCl falls between 15 and 30 mL/min.

Likewise, when dabigatran capsules are used to treat DVT or pulmonary embolism (PE), to reduce the risk of their recurrence, or for their prophylaxis following hip surgery, concomitant use should be avoided if CrCl is below 50 mL/min. For prophylaxis in patients whose CrCl is 50 mL/min or higher, the two agents should be given several hours apart.

In pediatric patients, the combination of dabigatran with P-gp has not been studied, although it may lead to higher dabigatran exposure.1 Irrespective of kidney function, caution may be needed when dabigatran is coadministered with moderate to strong P-gp inhibitors.3

The Dabigatran and Alogliptin Interaction, Explained

Dabigatran (Pradaxa) is a that helps prevent dangerous clots. Alogliptin (Nesina) helps lower blood sugar in type 2 diabetes. Your body uses a natural "pump" called to move dabigatran out, and alogliptin may slow that pump down a bit. If that happens, more dabigatran can stay in your blood, which can raise your chance of bleeding. This matters most if your kidneys do not work as well as they used to.

Watch for unusual bruising, nosebleeds, bleeding gums, or dark or bloody urine or stools. The good news is that your care team can manage this. Talk with your pharmacist or doctor so they can check your kidney function and set up the safest plan for you.

Mechanism: Dabigatran is a . Alogliptin is listed as a P-gp , and of intestinal P-gp efflux may increase dabigatran and exposure (/), raising bleeding risk. Note that alogliptin is not generally regarded as a moderate or strong P-gp inhibitor, so the magnitude is likely modest, but the interaction is rated major with probable evidence. Onset is unspecified.

  • Avoid in NVAF if CrCl is 15 to 30 mL/min.
  • Avoid for DVT/PE treatment, recurrence reduction, or post-hip surgery prophylaxis if CrCl is below 50 mL/min. If CrCl is 50 mL/min or more, separate doses by several hours for prophylaxis.
  • Not studied in pediatrics.
  • Assess function and monitor for signs of bleeding.

See the 4 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Dabigatran and Alogliptin Interact

The likely mechanism

of -mediated efflux transport of dabigatran

In short: Alogliptin slows P-glycoprotein, a pump that moves dabigatran out of cells, so more dabigatran can stay in the body.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Raises Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Dabigatran and Alogliptin Interaction

Your care team can manage this interaction by looking closely at your kidney function and why you take dabigatran.

  • If your kidneys filter more slowly, your team may choose a different combination of medicines.
  • In some situations, your team may have you take the two medicines several hours apart.
  • Your team may monitor you more closely for bleeding.

What you can do: Keep taking both medicines as prescribed. Tell your pharmacist or prescriber about any unusual bruising or bleeding, and ask whether your kidney function has been checked recently.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Dabigatran or Alogliptin need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

2 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses

    A 76-year-old woman residing in a nursing home, who was receiving dabigatran 150 mg twice daily for bilateral lower extremity DVTs along with low-dose quiNIDine (10 mg twice daily) for an unknown indication, was admitted with abdominal pain and rectal bleeding. Admission findings included anemia (Hb, 4.9 g/dL), coagulopathy (thrombin time (TT) greater than 60 seconds), acute kidney injury (SCr of 2 mg/dL; baseline 0.8 mg/dL), and an elevated BUN of 90 mg/dL.

    Her diagnosis was acute blood loss anemia secondary to lower bleeding, likely related to dabigatran use. Hemodialysis was not initiated because of the bleeding risk associated with catheter placement.

    Transfusion measures and idaruCIZUmab therapy initially normalized her Hb (8.2 g/dL) and TT (14.3 seconds); however, rebleeding occurred, and on repeat testing approximately 20 hours after idaruCIZUmab administration the TT had returned to greater than 60 seconds. Persistent coagulopathy, rectal bleeding, and impairment required a 10-day hospitalization, during which she received 2 additional doses of idaruCIZUmab on hospital days 2 and 4, and each dose produced only temporary normalization of coagulation parameters.

    Rectal bleeding persisted until day 5, when it began to improve, although TT stayed elevated until hospital day 9. Although reduced dabigatran in this case may have been partly due to renal impairment, quiNIDine (a ) was thought to have contributed to the initially suspected supratherapeutic dabigatran levels.4

  2. Report 2 · Study title

    Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function

    A comparative effectiveness study in patients with nonvalvular atrial fibrillation and normal kidney function found that the overall bleeding rate was 52% higher (244.9 vs 158.4 per 1000 person-years; HR, 1.52; 95% CI, 1.05 to 2.2) when dabigatran was coadministered with verapamil or dilTIAZem (n=750) than when it was coadministered with amLODIPine (n=1316), and 43% higher (291.3 vs 199.7 per 1000 patient-years; HR, 1.43; 95% CI, 1.02 to 2) with dabigatran plus verapamil or dilTIAZem (n=764) than with metoprolol (n=1334). Compared with amLODIPine, dabigatran plus verapamil or dilTIAZem was also associated with significant increases in overall () bleeding (HR, 2.16; 95% CI, 1.3 to 3.6), minor bleeding (HR, 1.56; 95% CI, 1.07 to 2.27), and GI minor bleeding (HR, 2.16; 95% CI, 1.29 to 3.63).

    Compared with metoprolol, dabigatran plus verapamil or dilTIAZem was associated with significant increases in overall GI bleeding (HR, 2.32; 95% CI, 1.42 to 3.79), major/moderate bleeding (HR, 3.32; 1.54 to 7.16), major/moderate GI bleeding (HR, 5.49; 95% CI, 1.67 to 18.03), and GI minor bleeding (HR, 2.33; 95% CI, 1.42 to 3.82). The dabigatran dose was 150 mg twice daily. Caution may be necessary when dabigatran is coadministered with verapamil and dilTIAZem, and possibly other moderate to strong , irrespective of kidney function.3

Dabigatran and Alogliptin: Common Questions

How serious is the Dabigatran and Alogliptin interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Dabigatran and Alogliptin interaction managed?

Your care team can manage this interaction by looking closely at your kidney function and why you take dabigatran. If your kidneys filter more slowly, your team may choose a different combination of medicines. In some situations, your team may have you take the two medicines several hours apart. Your team may monitor you more closely for bleeding. What you can do: Keep taking both medicines as pre… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Dabigatran and Alogliptin Interaction

Ask in your own words about taking Dabigatran and Alogliptin together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (4)

  1. Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2023. DailyMed
  2. Steffel J, Collins R, Antz M, et al: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23(10):1612-1676.
  3. Pham P, Schmidt S, Lesko L, et al: Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 2020; 3(4):e203593-. DOI
  4. George S, Taburyanskaya M, & Lewis V: Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. Blood Coagul Fibrinolysis 2019; 30(1):42-46. PubMed
Was this write-up helpful?

Other Serious Interactions of Dabigatran and Alogliptin

Also serious with Dabigatran

Also serious with Alogliptin

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Dabigatran

With Alogliptin

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.